Reported Earlier, Cytokinetics Presents New Safety Data on Aficamten at ESC 2024: Focus on Long-Term Use in HCM Patients
Reported Earlier, Cytokinetics Presents New Safety Data on Aficamten at ESC 2024: Focus on Long-Term Use in HCM Patients
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data related to the safety and long-term use of aficamten were presented in a Late Breaking Clinical Trial presentation and oral presentation at the European Society of Cardiology Congress 2024 in London, UK. The presentations included an integrated safety analysis from three clinical studies of aficamten and an analysis of the withdrawal of standard of care medications in patients treated with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM).
Cytokinetics公司（納斯達克股票代碼：CYTK）今天宣佈，在英國倫敦舉行的2024年歐洲心臟病學會議上，關於aficamten的安全性和長期使用的新數據進行了一個遲發性臨床試驗報告和口頭報告。報告包括aficamten的三項臨床研究的綜合安全性分析以及FORESt-HCm（Aficamten在肥厚性心肌病患者中的持續治療的後續研究評估）中接受aficamten治療的患者標準護理藥物撤退的分析，這是aficamten在肥厚性心肌病患者中的開放性標籤擴展臨床研究。
譯文內容由第三人軟體翻譯。
